Platelet-Rich Plasma vs Hyaluronic Acid for Osteoarthritis
Trial Summary
What is the purpose of this trial?
This is a single-center, prospective, randomized, single-blind, comparator therapy, parallel group study for symptomatic patients diagnosed with knee osteoarthritis. The aim is to demonstrate superior efficacy of platelet-rich plasma (PRP) as compared to hyaluronic acid (HA) in treating knee osteoarthritis. This aim will be objectively measured by endpoint consisting of changes in cartilage thickness from baseline in the MRI. The Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire will be used to calculate The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score. It will measure changes in pain and function from baseline. Approximately 100 subjects will be treated at NorthShore University HealthSystem (NorthShore) as part of this study. This study has the potential to improve outcomes in a very common chronic degenerative disease, osteoarthritis, which can have a significant effect on individuals' quality of life.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot use NSAIDs (non-steroidal anti-inflammatory drugs) 5 days before a blood draw or up to 7 days after the last PRP or HA treatment. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment Platelet-Rich Plasma vs Hyaluronic Acid for Osteoarthritis?
Research shows that both platelet-rich plasma (PRP) and hyaluronic acid (HA) are effective for treating knee osteoarthritis, with PRP often providing better pain relief and functional improvement than HA. However, the combination of PRP and HA has shown mixed results, and more studies are needed to confirm its effectiveness.12345
Is Platelet-Rich Plasma and Hyaluronic Acid treatment safe for humans?
How does the treatment of platelet-rich plasma (PRP) and hyaluronic acid (HA) differ from other treatments for osteoarthritis?
Platelet-rich plasma (PRP) and hyaluronic acid (HA) are unique non-surgical treatments for osteoarthritis that involve injecting substances directly into the joint to provide relief. PRP uses a patient's own blood to create a concentration of platelets that release growth factors, while HA acts as a lubricant to improve joint movement. These treatments aim to delay the need for surgery and offer an alternative to standard pain relief methods.49101112
Research Team
Jason L Koh, MD, MBA
Principal Investigator
Clinical Chairman, Dept. of Orthopaedics
Eligibility Criteria
This trial is for adults aged 18-75 with chronic knee pain from osteoarthritis, graded 2-3 on the K-L scale. Participants must have had pain for over three months and score at least a 40 on the VAS for pain. They should be able to consent and pass a physical exam, blood tests including platelet count, CRP, and ESR.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either PRP or HA injections for knee osteoarthritis treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- HA Treatment (Viscosupplementation)
- PRP Treatment (Platelet-Rich Plasma)
HA Treatment is already approved in Canada for the following indications:
- Knee osteoarthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Endeavor Health
Lead Sponsor
Gerald "J.P." Gallagher
Endeavor Health
Chief Executive Officer since 2022
MBA from Benedictine University
Sanjeeb Khatua, MD
Endeavor Health
Chief Physician Executive since 2023
MD from Rush Medical College
NorthShore University HealthSystem
Lead Sponsor
David Hall
NorthShore University HealthSystem
Chief Executive Officer since 2009
MBA in Healthcare Management, Western Governors University
Dr. Andi Arnautovic
NorthShore University HealthSystem
Chief Medical Officer since 1989
Residency at Mount Sinai Hospital, Chicago